Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CU 06

Next Previous
Search
Drug Profile

CU 06

Alternative Names: CU-06; CU-06-RE; CU06-1004; CU06-CERE/CV; CU06-EYE; CU06-HAE; CU06-IBD; CU06-ONCO; Sac-1004

Latest Information Update: 28 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CURACLE
  • Class Anti-inflammatories; Anti-ischaemics; Antineoplastics; Eye disorder therapies; Ischaemic heart disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Actin modulators; Chemokine CCL2 inhibitors; Histamine release inhibitors; Interleukin 1 beta inhibitors; Thrombin inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I Age-related macular degeneration
  • Research Unstable angina pectoris
  • No development reported Cancer; Crohn's disease; Diabetic retinopathy; Hereditary angioedema; Lung disorders; Macular degeneration; Myocardial infarction; Retinal oedema; Stroke; Ulcerative colitis

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer(Adjunctive treatment) in South Korea (PO)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Crohn's-disease in South Korea (PO)
  • 28 Oct 2023 No recent reports of development identified for preclinical development in Diabetic-retinopathy in South Korea (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top